000597NEP.SZSE

Northeast Pharmaceutical Group Co., Ltd.

东北制药

000597

Shenzhen Stock Exchange

BoardMain Board of Shenzhen Stock Exchange
IndustryPharmaceutical Manufacturing
ISINCNE0000009G0
ListedMay 23, 1996
Websitewww.nepharm.com.cn
IR Emaildshbgs@nepharm.com.cn
Phone024-25806963
AddressNo. 8, Kunminghu Street, Economic and Technological Development Zone, Shenyang, Liaoning

Company Profile

1.Brand Recognition As a traditional pharmaceutical enterprise, NorthEast Pharmaceutical Group Co., Ltd. enjoys high recognition within the industry. It holds solid market shares, particularly in products like Vitamin C, Levocarnitine, Piracetam, and Fosfomycin. Some of its products also occupy significant positions in the global market, with distinct advantages in quality and cost. 2.Large-Scale Production Capacity NorthEast Pharmaceutical Group Co., Ltd. possesses large-scale API production lines and strong cost control capabilities, granting it a price advantage in the global API market. Its products comply with both domestic and international quality standards, with several having obtained high-end international GMP certifications such as EDQM, Japan, South Korea, and Brazil, securing an important position in the international supply market. Through the integration and coordination of APIs and formulations, the company ensures formulation product quality and achieves comprehensive improvements in drug safety, efficacy, and stability. 3.Advantages in Comprehensive Environmental Protection NorthEast Pharmaceutical Group Co., Ltd. consistently adheres to the principle of "Safety first, environmental protection prioritized". It continuously increases investment in environmental protection facilities, clean production processes, and compliance management. Its supporting wastewater treatment installations enable separate treatment of high and low concentration streams. The company has built its own solid-liquid hazardous waste incineration unit to increase the self-sufficiency rate in hazardous waste disposal. For exhaust gases, it employs a combination of processes including RTO, CO (Catalytic Oxidation), activated carbon adsorption/desorption, scrubbing, and bag filtration for classified and synergistic treatment. The company actively promotes green and low-carbon transformation to achieve sustainable development. 4.Robust R&D Foundation NorthEast Pharmaceutical Group Co., Ltd. has established a Pharmaceutical Research Institute focused on drug R&D, possessing strong capabilities in efficient generic drug application submissions and bioequivalence (BE)/consistency evaluations. Furthermore, the company maintains long-term collaborations with renowned research institutions such as the Chinese Academy of Sciences and Shenyang Pharmaceutical University, accumulating rich technical expertise in API process optimization. 5.Cell Therapy Field Beijing Dingcheng Peptide Source Biotechnology Co., Ltd., a holding subsidiary of NorthEast Pharmaceutical Group Co., Ltd., possesses unique advantages in the research of specific cellular immunotherapy technologies, product development, and clinical applications. These advantages include a distinctive technology platform, first-mover market positioning, a rich product pipeline, and the capability for rapid clinical application.

Full description

NorthEast Pharmaceutical Group Co., Ltd. (NEPG) operates across multiple sectors including chemical pharmaceuticals (covering APIs and formulations), pharmaceutical distribution (wholesale and chain retail), pharmaceutical engineering (design, manufacturing, and installation), and biopharmaceuticals (bio-diagnostic reagents), establishing a comprehensive cluster integrating the upstream and downstream pharmaceutical industry and services. The company boasts a diverse product portfolio comprising ten major series: vitamins, anti-infectives, reproductive system and sex hormones, nervous system drugs, anti-AIDS drugs, digestive system drugs, narcotic and psychotropic substances, other generic drugs, in vitro (bio) diagnostic reagents, and the health and wellness sector. It possesses over 400 varieties of chemical APIs, pharmaceutical intermediates, and formulation products. Beijing Dingcheng Peptide Source Biotechnology Co., Ltd., a holding subsidiary of NorthEast Pharmaceutical Group Co., Ltd., is dedicated to the R&D of TCR-T, TCR protein drugs, and CAR-T cell therapy products by establishing its own independent core technology platform.

Announcements

0 shown